新华医疗：公司收购中帜生物股权尚未取得股转中心批复

Core Viewpoint - Xinhua Medical (600587) has stated that the acquisition of Zhongzhi Biological equity has not yet received approval from the share transfer center, and it will not impact the company's performance [1] Group 1 - The acquisition of Zhongzhi Biological equity is still pending approval [1] - The company reassures investors that the acquisition will not affect its financial results [1]